Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) Dividend History

Enlivex Therapeutics Ltd. is a clinical-stage biotech company specializing in the development of immune rebalancing immunotherapies for the treatment of severe inflammatory and immune-related conditions. Their flagship product pipeline focuses on harnessing the body's immune system to improve outcomes in conditions such as sepsis, graft-versus-host disease, and other immune dysregulation disorders.

Website:

Dividend History

Enlivex Therapeutics Ltd. Ordinary Shares currently does not pay dividends

Company News

  • Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

    Enlivex Therapeutics received a notice of allowance for a Japanese patent application covering the use of its Allocetra™ product in treating osteoarthritis, a common and debilitating condition with limited treatment options.

    GlobeNewswire Inc.
  • Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

    Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants, for aggregate gross proceeds of approximately $5.0 million.

    GlobeNewswire Inc.
  • Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

    Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants.

    GlobeNewswire Inc.
  • Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

    Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health (IMOH) in January.

    GlobeNewswire Inc.
Dividend data last updated 06/06/2025 23:29:27 UTC